Detection of Serum CSLEX Levels in Breast Cancer Patients

Simple item page
dc.contributor.authorDanai Tiwawechen_US
dc.contributor.authorWanchalerm Nunvititpongen_US
dc.contributor.authorAdisak Sornpromen_US
dc.contributor.authorArkom Chaiwerawattanaen_US
dc.contributor.authorChanin Apiwanichen_US
dc.date.accessioned2011-02-22T08:15:50Z
dc.date.available2011-02-22T08:15:50Z
dc.date.created2011-02-11en_US
dc.date.issued2011-02-11en_US
dc.description.abstractBreast cancer (BRC) is an important malignant disease. Its incidence is highest among the female cancers in Thailand, with a trend to increase annually. The discovery of new tumor markers is urgently needed, to enable BRC to be detected in its early stages, to improve prognosis, to monitor treatment, and to detect recurrence, and thereby control this serious neoplasm. It has been reported that CSLEX (sialyl LewisX), a cancer-associated carbohydrate antigen on cancer-cell membrane, can be detected in the serum of cancer patients at higher levels than healthy controls; it can be used for monitoring the treatment of patients with cancers of the lung, stomach, colon, and breast. The aims of this study were to investigate differences in the serum CSLEX levels of BRC patients and healthy controls, and the correlation of serum CSLEX levels with stages and histological types. The level of serum CSLEX was measured in 200 breast-cancer patients and 200 healthy controls by enzyme immunoassay technique. The average level of serum CSLEX in the breast-cancer group was 12.14 + 15.70 U/ml (mean + SD) which was significantly higher than the healthy control group (3.56 + 2.41 U/ml) (p\<0.001). In the healthy control group, the cutoff value was 8.38 U/ml (mean + 2SD). The sensitivity and specificity of serum CSLEX for the detection of BRC were 69.0% and 98.0%, respectively. The serum CSLEX levels increased among the advanced-stage BRC patients. However, no correlation was found between serum CSLEX level and histological type. The findings of this study suggest that the detection of serum CSLEX level may be a useful tool for the diagnosis and prognosis of breast cancers among Thai women. (Thai Cancer J 2010;30:145-152)en_US
dc.identifier.citationThai Cancer Journal; Vol.30 No.4 October-December 2010; 145-152en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/132396
dc.language.isoen_USen_US
dc.publisherThai Cancer Journalen_US
dc.rightsNational Cancer Institute of Thailand, Bangkok, Thailanden_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/TCJ/issue/archiveen_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/TCJ/article/view/5285en_US
dc.titleDetection of Serum CSLEX Levels in Breast Cancer Patientsen_US
dc.typeResearch Articlesen_US
Files
Collections
Thai Cancer Journal